Truebeam容积调强技术对胶质瘤患者的治疗效果及预后影响分析

Effect of Truebeam Volume Intensity Modulated Imaging on the Treatment and Prognosis of Patients with Glioma

目的:研究Truebeam容积调强技术对胶质瘤患者的治疗效果及预后影响。方法:纳入研究对象共60例,均为医院从2018年2月~2021年2月收治的胶质瘤患者。根据患者治疗方式的差异分为研究组及常规组,每组各30例。常规组实施调强适形放疗,研究组则开展Truebeam容积旋转调强放疗。结果:在总有效率方面对比,研究组高于常规组(P<0.05)。治疗后,研究组血清EGF以及VEGF水平分别为(1175.20±215.90)pg/mL、(180.40±14.58)ng/L,相较于常规组的(1345.78±308.48)pg/mL、(232.59±21.37)ng/L均较低(P<0.05)。治疗后研究组及常规组生活质量综合评定问卷-74(GQOLI-74)评分均高于治疗前,且研究组高于常规组(P<0.05)。研究组6个月、12个月及18个月存活率均高于常规组(P<0.05)。结论:Truebeam容积调强技术对胶质瘤患者的治疗效果较佳,且有效改善患者预后。

Objective:To study the effect of Truebeam volume modulation on the treatment and prognosis of patients with glioma.Methods:A total of 60 subjects were included in the study,all of whom were glioma patients admitted to the hospital from February 2018 to February 2021.The patients were divided into study group and routine group according to the difference of treatment methods,with 30 patients in each group.The conventional group received IMRT,while the study group received Truebeam volume rotation IMRT.Results:The total effective rate of the study group was higher than that of the routine group(P<0.05).After treatment,the serum levels of EGF and VEGF in the study group were(1175.20±215.90)pg/mL and(180.40±14.58)ng/L respectively,which were lower than those in the control group(1345.78±308.48)pg/mL and(232.59±21.37)ng/L(all P<0.05).The scores of GQOLI-74 in the study group and the routine group after treatment were higher than those before treatment,and those in the study group were higher than those in the routine group(all P<0.05).The 6-,12-and 18-month survival rates in the study group were higher than those in the control group(all P<0.05).Conclusion:Truebeam volume intensity modulated imaging is effective in the treatment of patients with glioma,and it can improve the prognosis of the patients.